Almokalant是一个新的Ⅲ类抗心律失常药。它延长心房/心室的单相动作电位和不应期,不影响传导速度,具有正性肌力作用,无β受体阻滞效应。 10例恢复期心肌梗塞伴室性心律失常患者,在24小时Holter监测中室性早搏次数≥720次或非持续性室速发作≥10次。随机静脉滴注almokalant 4.5mg(12.8μmol)或安慰剂,10分钟滴完;次日两者交换。滴注almokalant前后,心率、心电图PR间期和QRS时限无明显变化。滴注后,QTc间期由445±15延长至548±53毫秒(p=0.0015),持续120分钟;室性早搏的联 Almokalant is a new Class III anti-arrhythmic drug. It extends the atrial / ventricular single-phase action potential and refractory period, does not affect the conduction velocity, with positive inotropic effect, no beta-blockade effect. In 10 patients with convalescent myocardial infarction with ventricular arrhythmia, ≥720 ventricular premature beats or ≥10 episodes of non-sustained ventricular tachycardia were recorded at 24-hour Holter monitoring. Randomized intravenous infusion of almokalant 4.5mg (12.8μmol) or placebo, drip finished 10 minutes; the next day the two exchange. Before and after instillation of almokalant, there was no significant change in heart rate, ECG PR interval and QRS duration. After instillation, the QTc interval was prolonged from 445 ± 15 to 548 ± 53 ms (p = 0.0015) for 120 minutes; the association of premature ventricular contractions